{"entity":{"id":"nct05945823","kind":"trial","name":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","aka":[],"tldr":"A phase 2 trial of Futibatinib, Pembrolizumab, Cisplatin and Oxaliplatin in oesophageal cancer and pancreatic ductal adenocarcinoma, run by Taiho Oncology, Inc., active and no longer recruiting.","summary":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors is a phase 2 interventional study registered as NCT05945823 by Taiho Oncology, Inc., with 53 participants enrolled, started 2023-07-13 and due to reach its primary completion in 2026-10-01. Interventions recorded: Futibatinib, Pembrolizumab, Cisplatin, 5-FU, Oxaliplatin and Leucovorin.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05945823","url":"https://clinicaltrials.gov/study/NCT05945823"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["esophageal","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["futibatinib","pembrolizumab","cisplatin","oxaliplatin"],"companies":["araris"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05945823","phase":"2","setting":"A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors.","sponsor":"Taiho Oncology, Inc.","enrolled":53,"outcomes":[]},"route":"/trials/nct05945823/","neighbours":{"cancer":[{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"futibatinib","kind":"drug","name":"Futibatinib","route":"/drugs/futibatinib/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"araris","kind":"company","name":"Araris Biotech (Taiho)","route":"/companies/araris/"}]}}